Q1 2024 13F Holders as of 3/31/2024
-
Type / Class
-
Equity / COMMON STOCK
-
Shares outstanding
-
130M
-
Number of holders
-
235
-
Total 13F shares, excl. options
-
118M
-
Shares change
-
+15.3M
-
Total reported value, excl. options
-
$8.05B
-
Value change
-
+$1.06B
-
Put/Call ratio
-
0.75
-
Number of buys
-
137
-
Number of sells
-
-89
-
Price
-
$68.31
Significant Holders of Vaxcyte, Inc. - COMMON STOCK (PCVX) as of Q1 2024
265 filings reported holding PCVX - Vaxcyte, Inc. - COMMON STOCK as of Q1 2024.
Vaxcyte, Inc. - COMMON STOCK (PCVX) has 235 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 118M shares
of 130M outstanding shares and own 90.67% of the company stock.
Largest 10 shareholders include FMR LLC (16.3M shares), VANGUARD GROUP INC (9.74M shares), BlackRock Inc. (9.51M shares), RA CAPITAL MANAGEMENT, L.P. (8.2M shares), JANUS HENDERSON GROUP PLC (7.67M shares), WELLINGTON MANAGEMENT GROUP LLP (4.92M shares), Capital Research Global Investors (4.14M shares), T. Rowe Price Investment Management, Inc. (3.55M shares), STATE STREET CORP (3.34M shares), and PRICE T ROWE ASSOCIATES INC /MD/ (3.18M shares).
This table shows the top 235 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.